- Our Company
- Our Strategy
- Governance
- Social Impact
- Access to Healthcare
- Innovation for Vulnerable Communities
- Environmental Sustainability and Resilience
- Diversity, Equity, and Inclusion In and Beyond the Workplace
- A Million Conversations
- Allyship
- Employee Resource Groups
- Diversity, Equity and Inclusion Board
- Gender Balance
- LGBTQ+
- Responsible Business Values
- Our Legacy
- Our Science
- Our Pipeline
- R&D Focus Areas
- Immunology R&D
- Neurology R&D
- Oncology R&D
- Rare Blood Disorders R&D
- Rare Diseases R&D
- Vaccines R&D
- Artificial Intelligence in R&D
- Technology Platforms
- Clinical trials & results
- Our Data-Sharing Commitments
- Clinical Study Results
- Investigator Sponsored Studies
- Diversity in Clinical Trials
- Scientific Collaboration
- Your Health
- Vaccines
- COVID-19
- Dengue
- Diphtheria
- Haemophilus influenzae type b infections
- Hepatitis A
- Hepatitis B
- Influenza
- Meningococcal meningitis
- Pertussis
- Poliomyelitis
- Rabies
- Respiratory Syncytial Virus
- Tetanus
- Typhoid fever
- Yellow fever
- Production
- Why vaccines matter
- How immunization works?
- Medicines
- Consumer Healthcare
- Patient Support
- Healthcare Professionals Support
- Relations with Healthcare Professionals and Healthcare Organizations Bosnia and Herzegovina
- Relations with Healthcare Professionals and Healthcare Organizations in Bulgaria
- Relations with Healthcare Professionals and Healthcare Organizations in Croatia
- Relations with Healthcare Professionals and Healthcare Organizations in Cyprus
- Relations with Healthcare Professionals and Healthcare Organizations in Estonia
- Relations with Healthcare Professionals and Healthcare Organizations in Latvia
- Relations with Healthcare Professionals and Healthcare Organizations in Lithuania
- Relations with Healthcare Professionals and Healthcare Organizations in Malta
- Relations with Healthcare Professionals and Healthcare Organizations in North Macedonia
- Relations with Healthcare Professionals and Healthcare Organizations in Serbia
- Relations with Healthcare Professionals and Healthcare Organizations in Slovenia
- Managed Access Programs (MAPs)
- Pre-Registration Import Licenses
- Post Trial Access (PTA)
- Partnering
- Partnering Focus Areas
- China
- Digital
- General Medicines
- Immunology
- Neuroscience
- Oncology
- Out-Licensing
- Rare Disease
- Technology Platforms
- Vaccines
- Meet the Partnering Team
- Oncology Golden Ticket
- Media
- Press Statements
- Statement issued in accordance with the Indian Taxation Laws (Amendment) Act, 2021 read with the relevant Rules
- Statement Regarding Düsseldorf Regional Court Decision in Ongoing Praluent® (alirocumab) Patent Litigation in Germany
- Statement Regarding Decision of Opposition Division of the European Patent Office Regarding Amgen Patent Targeting PCSK9
- Press Releases
- Media Contacts
- Sanofi response to the situation in Ukraine
- Investor Relations
- Financial Results and Investor Events
- Environment, Social, Governance
- Individual Shareholders
- Shares and ADRs
- Sanofi stock chart
- Dividends
- ADRs
- Shareholding structure
- Vara consensus
- Shares & voting rights
- Share repurchases
- Financial Reports and Publications
- Financial Reports and Regulated Information
- Shareholder publications
- Financial Reporting Center and Key Data
- Contacts
- Tender offer by Sanofi to acquire Ablynx
- Fixed income
- Careers
- Paris 2024 Partnership
- Legal notice
- Our publications
- Directory
- Sanofi Today
- Rss feed